

# Prophylactic Human Vaccines: Market Research Report

<https://marketpublishers.com/r/PD857ACD826EN.html>

Date: January 2016

Pages: 358

Price: US\$ 4,950.00 (Single User License)

ID: PD857ACD826EN

## Abstracts

This report analyzes the worldwide markets for Prophylactic Human Vaccines in US\$ Million by the following Product Segments: Pediatric Prophylactic Vaccines, and Adult Prophylactic Vaccines.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022.

Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs.

The report profiles 63 companies including many key and niche players such as -

ALK Abelló A/S

Altimune, Inc.

Bavarian Nordic A/S

BiondVax Pharmaceuticals Ltd.

Bharat Biotech International Limited

## Contents

### **I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS**

Study Reliability and Reporting Limitations  
Disclaimers  
Data Interpretation & Reporting Level  
Quantitative Techniques & Analytics  
Product Definitions and Scope of Study  
Prophylactic Vaccines

### **II. EXECUTIVE SUMMARY**

#### **1. MARKET OVERVIEW & OUTLOOK**

Human Vaccines: A Prelude  
Human Vaccines Market – A Snapshot  
Market Dynamics  
Growth Drivers in a Capsule  
Developed World: The Key Markets  
Emerging Markets: The Future Growth Area  
Vaccine Pricing: The Developed – Developing Divide

#### **2. MARKET TRENDS & ISSUES**

Prophylactic Pediatric Vaccines – A Mature Market  
Emerging Nations Offer Huge Opportunities for Pediatric Vaccine Manufacturers  
Rising Incidence of Infectious Diseases to Fuel Growth of Anti-Infective Vaccines  
Novel Vaccines against Emerging Infectious Diseases  
Ongoing Developments for a Vaccine against Zika Virus  
Sanofi's Dengue Vaccine First-to-Market  
Pipeline & Marketed Dengue Vaccine: 2016  
Computational Tools Come to Aid in Development of Ebola Vaccines  
Vaccine for AIDS  
Ongoing Research for HIV Vaccine & Commercial Pipeline  
List of Clinical Trial (Phase II) AIDS Vaccines: 2015  
Staggering Global Statistics of AIDS – Opportunity Indicator

**Table 1.** HIV Infection Statistics Worldwide: As of 2014 (includes corresponding Graph/Chart)

**Table 2.** Worldwide HIV Prevalence and Incidence (in Million) by Region: 2014 (includes corresponding Graph/Chart)

**Table 3.** Worldwide AIDS related Deaths by Geographic Region: 2014 (includes corresponding Graph/Chart)

**Table 4.** HIV-Positive Individuals, by Gender (2014): Percentage Breakdown of Women and Men Tested HIV-Positive in all WHO Regions (includes corresponding Graph/Chart)

Vaccination-Autism Link and Other Safety Concerns Thwarted

Threat of Pandemic Rejuvenates Vaccine Market

Influenza Vaccines on a Growing Spree

Influenza Vaccines on the Current Market: 2016

H1N1 Vaccines Hit the Market in August 2009

H1N1 Influenza Vaccines and Manufacturers

Influenza Market Faces Several Challenges

Rising Disease Incidence and Increasing Awareness Drive the Global Meningococcal Vaccines Market

Unmet Demand for TB Vaccine

Key TB Vaccine Candidates in the Pipeline: 2016

Need for a Human Vaccine for Leishmaniasis

Economic Factors Hamper Optimal Vaccine Development and Delivery

Increasing Need for Vaccine Promotion in the Developing Regions

Changing Vaccine Needs

Religious Concerns over Immunizing Young Girls against Human Papillomavirus

Changing Travel Patterns Increase Demand for Hepatitis B Vaccine

DNA Vaccines: Engineering Growth

Noninjectable Vaccines: Gain without Pain

Application of Botulinum Toxin as Delivery Mechanism for Oral Vaccines

Conjugate Vaccines: A Technological Innovation

Hib Vaccines on the Market: 2016

Growing Pricing Pressure – A Major Market Deterrent

Safety Issues Come to the Fore

BioWarfare: Threat Perception and Preparedness

Overview of Potential Bio-Terrorist Agents

Smallpox (Variola Major)  
Anthrax (Bacillus Anthracis)  
Plague (Yersinia Pestis)  
Botulism (Clostridium Botulinum)  
Tularemia (Francisella Tularensis)  
Tackling Cold Chain Issues  
Trade Statistics

**Table 5.** Global Exports of Human Vaccines by Leading Country (2013, 2014 & 2015): Percentage Share Breakdown of Export Value for Leading Exporters (includes corresponding Graph/Chart)

**Table 6.** Global Imports of Human Vaccines by Leading Country (2013, 2014 & 2015): Percentage Share Breakdown of Import Value for Leading Importers (includes corresponding Graph/Chart)

### 3. COMPETITIVE LANDSCAPE

Competitive Scenario  
Leading Players

**Table 7.** Leading Players in the Global Human Vaccines Market (2015): Annual Sales in US\$ Million for GlaxoSmithKline, Merck, Pfizer and Sanofi (includes corresponding Graph/Chart)

**Table 8.** Top Five Human Vaccines Worldwide by Sales Value: 2015 (In US\$ Million) (includes corresponding Graph/Chart)

Pfizer Scores Big with Prevnar  
Trumenba Shows Promise in Phase III Clinical Trials  
GSK Takes Big Leap into the Meningococcal Vaccine Market  
Acquired Products Strengthen GSK's Vaccines Sales  
The Potential for MenABCWY Vaccine

**Table 9.** US Meningococcal Disease Incidence by Serogroup Distribution (1990 & 2013): Percentage Breakdown of Disease Incidence for Serotypes B, C, Y and Others

(includes corresponding Graph/Chart)

Sanofi Works on Production Issues to Boost Sales

New Vaccines to Enhance Prospects for Sanofi

Sanofi's Human Vaccine R&D Pipeline

Weaker Sales Drive Merck and Sanofi's European JV Split

Serum Institute to Stir Competitive Landscape in the HPV Vaccine Market

#### **4. PRODUCT OVERVIEW**

Introduction to the Concept of Immunity

Role of Vaccines in Strengthening the Immune System

Vaccines and Immunotherapy

Historical Overview of Vaccines

How it Began

So Far So Good

Successful Vaccine Introductions in the Past

Contribution of Animal Research to Vaccine Production

Types of Vaccines

Live, Attenuated Vaccines

Combination Vaccines

Killed or Inactivated Vaccines

DNA & Recombinant DNA Vaccines

Toxoids

Cellular Fractions

Conjugate Vaccines

Subunit Vaccines

Passive Immunization

Prophylactic Vaccines

Prevention Better than Cure

Prophylactic Pediatric Vaccines

Vaccination over the Years

BCG Vaccine

Growth Boosting Factors for TB Vaccines

Demand Restraining Factors for TB Vaccines

Major Issues to be addressed in the TB Vaccine Market

Hemophilus Influenza Type B Vaccine

Diphtheria/Tetanus/Pertussis Vaccines

Hepatitis A Vaccine

Hepatitis B Vaccine  
Hepatitis B Epidemiology  
Measles/Mumps/Rubella Vaccines  
Rotavirus Vaccines  
Polio Vaccines  
Varicella Vaccine  
Combination Vaccines  
Prophylactic Adult Vaccines  
Hepatitis A Vaccine  
Hepatitis B Vaccines  
Key Issues Affecting the Adult Hepatitis Vaccines Market  
Cholera Vaccine  
Japanese Encephalitis Vaccines  
Influenza Vaccines  
Influenza A Virus  
Influenza A (H1N1) Virus  
Vaccine Virus Selection for the 2015-2016 Influenza Season  
WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Northern Hemisphere for 2015-2016  
WHO Recommended Virus Strains for Seasonal Influenza Vaccines for Southern Hemisphere for 2015-2016  
Lyme Disease Vaccine  
Pneumococcal Disease Vaccines  
Meningococcal Vaccines  
Rabies Vaccines  
Typhoid Vaccine  
Yellow Fever Vaccine  
Mechanisms for Vaccine Delivery  
Edible Vaccines  
Oral Vaccines  
Tablet Based Vaccines  
Mucosal Delivery  
Transdermal Patch Delivery  
Storage Problems  
Perfluorocarbons as Alternative to Overcome Storage Problems  
Costs  
Standards for Vaccine Safety and Quality

## **5. CLINICAL TRIALS IN THE VACCINES MARKET**

Inovio and GeneOne to Initiate Phase 1 Human Trial for Zika DNA Vaccine  
Takeda Begins Phase2b Trial for World's First Norovirus Vaccine  
Bavarian Nordic Announces Positive Results from Phase 1 Trial of RSV Vaccine  
Investigational Vaccine for P. vivax Malaria Enters Human Trials  
Valneva Reports Postive Phase 2 Results for Vaccine Candidate against C. difficile  
Novavax Announces Positive Phase 2 Clinical Trial Results for RSV-F Protein Vaccine  
Vical Reports Postive Preclinical Data for CyMVectin CMV vaccine  
Profectus BioSciences Receives HHS Contract to Accelerate Ebola Vaccine Candidate into Clinical Studies  
Inovio and GeneOne to Advance Ebola Vaccine into Phase 1 Trial

## **6. PRODUCT LAUNCHES/APPROVALS**

FDA Approves 2016/17 Formulation of Protein Sciences Corporation's Flublok  
Sanofi's Dengue Vaccine Approved in Costa Rica  
GSK Supplies Flu Vaccines based on Valneva's EB66 Cell Line  
FDA Approves Seqirus' FLUCELVAX QUADRIVALENT Influenza Vaccine  
China Launches HFMD Vaccine  
Bharat Biotech Introduces ZIKAVAC Vaccine for Zika Infection  
Sanofi Pasteur Launches Vaccine R&D Project for Zika Virus Infection  
WHO Accepts Merck's Investigational Ebola Vaccine Application for Review  
Sanofi's Dengvaxia Receives Marketing Authorization in Mexico  
SK Chemicals Launches Influenza Vaccine SKYCellflu  
Sanofi Pasteur Ships First Doses of Fluzone for the US Market  
Bharat Biotech Launches Made-in-India ROTAVAC Vaccine  
FDA Approves Sanofi's sBLA for Fluzone Vaccine  
FDA Approves Merck's HPV Vaccine GARDASIL9  
Sanofi Pasteur Launches Shan5 Vaccine Developed by its Affiliate Shantha  
US FDA Approves First Meningococcal Disease Vaccine Trumenba

## **7. RECENT INDUSTRY ACTIVITY**

WHO Prequalifies Four-dose, Multi-dose Vial Presentation of Pfizer's Prevnar  
Sanofi Pasteur Begins Vaccine Manufacturing at Its Affiliate Shantha Biotechnics' Facility  
Bavarian Nordic Announces IMVAMUNE Supply Contract with US Government  
Stellar Biotechnologies and Neovacs Form JV to Develop Conjugated Vaccines  
WHO Recommends Sanofi's Dengvaxia in Nations with Widespread Dengue

Kaketsuken to Sell Vaccines Business to Astellas  
Sanofi and Merck End Joint Venture on Vaccines  
GeoVax Labs Collaborates with USAMRID for Hemorrhagic Fever Vaccine  
Bavarian Nordic Collaborates with Evaxion for Vaccine against MRSA  
Bavarian Nordic Enters into License Agreement with Janssen  
CSL Rebrands Influenza Vaccines Business as Seqirus  
MedImmune Joins Human Vaccines Project for Cancer and Infectious Disease Vaccine R&D  
GlaxoSmithKline Acquires Novartis' Vaccines Business  
Vaxin Changes Name to Altimune  
Takeda Expands Commercialization Agreement with Nanotherapeutics  
MedImmune Enters Into License Agreement with Inovio Pharmaceuticals  
CSL Completes Acquisition of Novartis' Influenza Vaccines Business  
Pfizer to Acquire Meningitis Vaccines from GSK  
Pfizer Stops Prevnar Vaccine Sales in China After Government Fails to Renew License  
Takeda Transfers HPV Vaccine License Agreement to Kaketsuken  
GlaxoSmithKline Acquires GlycoVaxyn  
Pfizer Acquires Redvax GmbH  
Pfizer Acquires Baxter's Vaccines and Portion of Manufacturing Facility

## **8. FOCUS ON SELECT PLAYERS**

ALK – Abello A/S (Denmark)  
Altimune, Inc. (US)  
Bavarian Nordic A/S (Denmark)  
BiondVax Pharmaceuticals Ltd. (Israel)  
Bharat Biotech International Limited (India)  
GlaxoSmithKline Plc. (UK)  
Hualan Biological Engineering Inc. (China)  
Janssen Pharmaceuticals, Inc. (US)  
MedImmune (US)  
Merck & Co., Inc. (US)  
Pfizer Inc. (US)  
Sanofi Pasteur SA (France)  
Serum Institute of India Pvt. Ltd. (India)  
Shanghai BravoBio Co., Ltd. (China)  
Seqirus (UK)  
SK Chemicals Co., Ltd. (Korea)  
Takeda Pharmaceutical Company Limited (Japan)



Zydus Cadila (India)

## 9. GLOBAL MARKET PERSPECTIVE

**Table 10.** World Recent Past, Current & Future Analysis for Prophylactic Human Vaccines Prophylactic by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 11.** World Historic Review for Prophylactic Human Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 12.** World 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 13.** World Recent Past, Current & Future Analysis for Pediatric Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 14.** World Historic Review for Pediatric Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 15.** World 14-Year Perspective for Pediatric Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 16.** World Recent Past, Current & Future Analysis for Adult Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan),

Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 17.** World Historic Review for Adult Prophylactic Vaccines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 18.** World 14-Year Perspective for Adult Prophylactic Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), Latin America and Rest of World Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

### III. MARKET

#### 1. THE UNITED STATES

##### A. Market Analysis

Outlook

Key Growth Drivers

Select Market Constraints

Major Trends in the US Vaccines Development

Increasing Consolidation Activity among Companies

Combination Vaccines and New Delivery Models Gaining Traction

Protests against Vaccination Make Companies More Cautious

Technological Challenges in the Development of RSV Vaccines

Pediatric Vaccines Market

Improved Pricing Scenario for Pediatric Vaccines

Market Focus Shifting from Pediatric Vaccines

Growth Drivers for US Pediatric Vaccines Market

Demand Restraining Factors for US Pediatric Vaccines Market

Opportunity Indicators

**Table 19.** Number of Reported Cases for Vaccine-Preventable Diseases in American Regions: 2009-2013

**Table 20.** Routine Immunization Coverage in the US (2011-2013): Percentage of Live

Births/New Borns/Infants/Children Vaccinated (includes corresponding Graph/Chart)

The US Influenza Vaccine Market  
'Swine Flu' Strain Returns in the 2013-14 Season

**Table 21.** CDC Price List for Pediatric Influenza Vaccines in Basic Package: 2015-2016

**Table 22.** CDC Price List for Adult Influenza Vaccines in Basic Package: 2015-2016

A Background on the Need for Flu Vaccines  
Need for Immunization Schedule for Adults  
Vaccines and Intended User Group  
Adult Population: To Drive Future Growth of Pertussis Vaccines Market

**Table 23.** Pertussis Cases (In Thousands) for Years 2000 through 2014 (includes corresponding Graph/Chart)

Vaccine Pricing in the US  
Regulatory Environment  
Review Process Make Vaccines Safer  
Imports-Exports Scenario

**Table 24.** US Exports of Human Vaccines by Country (2014 & 2015) - Percentage Breakdown of Export Value for Leading Destinations (includes corresponding Graph/Chart)

**Table 25.** US Imports of Human Vaccines by Country (2014 & 2015): Percentage Breakdown of Import Value for Leading Countries of Origin (includes corresponding Graph/Chart)

Clinical Trials  
Product Launches  
Strategic Corporate Developments  
Select Players  
B. Market Analytics

**Table 26.** US Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 27.** US Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 28.** US 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## **2. CANADA**

### A. Market Analysis

#### Outlook

#### Opposition to CMA's Mandatory Vaccination Program

### **2009 H1N1 PANDEMIC BOOSTS VACCINES SALES**

#### Trade Statistics

**Table 29.** Canadian Exports of Human Vaccines by Country (2014 & 2015): Percentage Breakdown of Export Value for Leading Destinations (includes corresponding Graph/Chart)

**Table 30.** Canadian Imports of Human Vaccines by Country (2014 & 2015): Percentage Breakdown of Import Value for Leading Countries of Origin (includes corresponding Graph/Chart)

### B. Market Analytics

**Table 31.** Canadian Recent Past, Current & Future Analysis for Prophylactic Human

Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 32.** Canadian Historic Review for Prophylactic Human Vaccines by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 33.** Canadian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

### 3. JAPAN

#### A. Market Analysis

##### Outlook

Controversy, Confusion and Hasty Actions Murr HPV Vaccination Market

Strategic Corporate Developments

Key Japan-based Player – Takeda Pharmaceutical Company Limited

#### B. Market Analytics

**Table 34.** Japanese Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 35.** Japanese Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 36.** Japanese 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## 4. EUROPE

### A. Market Analysis

#### Outlook

#### Vaccine Pricing in Europe

#### Major Drawbacks

#### Regulatory Mechanism for Vaccines in Europe

#### An Insight into European Influenza Vaccination Scenario

#### H3N2 Viruses Predominate in the 2014/15 Season; H1N1 Still in Circulation

#### Cell-based Vaccine Production Remains Nascent, Egg-based widely used

#### EU Welcomes Quadrivalent LAIVs

#### Major Influenza Vaccines Available in European Union Member Countries

#### Major H1N1 Flu Vaccines Available in Select East European Markets

### B. Market Analytics

**Table 37.** European Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 38.** European Historic Review for Prophylactic Human Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 39.** European 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region - Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 40.** European Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 41.** European Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years

2009 through 2014 (includes corresponding Graph/Chart)

**Table 42.** European 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

#### **4A. FRANCE**

A. Market Analysis

Outlook

Clinical Trial

Product Launches

Strategic Corporate Developments

Key Players

B. Market Analytics

**Table 43.** French Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 44.** French Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 45.** French 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

#### **4B. GERMANY**

Market Analysis

**Table 46.** German Recent Past, Current & Future Analysis for Prophylactic Human

Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 47.** German Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 48.** German 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

#### **4C. ITALY**

Market Analysis

**Table 49.** Italian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 50.** Italian Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 51.** Italian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

#### **4D. THE UNITED KINGDOM**

A. Market Analysis

Outlook

Product Launch



Strategic Corporate Developments

Select Players

B. Market Analytics

**Table 52.** UK Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 53.** UK Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 54.** UK 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

#### **4E. SPAIN**

Market Analysis

**Table 55.** Spanish Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 56.** Spanish Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 57.** Spanish 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## 4F. RUSSIA

### Market Analysis

**Table 58.** Russian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 59.** Russian Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 60.** Russian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## 4G. REST OF EUROPE

### A. Market Analysis

Outlook

Clinical Trial

Strategic Corporate Developments

Select Players

### B. Market Analytics

**Table 61.** Rest of Europe Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 62.** Rest of Europe Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 63.** Rest of Europe 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## 5. ASIA-PACIFIC

### A. Market Analysis

Outlook

Asian Vaccine Industry

Challenges

### 2014-15: DEADLIEST SWINE FLU SEASON IN INDIA SINCE 2009

Leading Influenza H1N1 Vaccine Brands Available in Select Asia-Pacific Markets

### B. Market Analytics

**Table 64.** Asia-Pacific Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 65.** Asia-Pacific Historic Review for Prophylactic Human Vaccines by Geographic Region/Country - China, India, and Rest of Asia-Pacific Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 66.** Asia-Pacific 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region/Country - Percentage Breakdown of Dollar Sales for China, India, and Rest of Asia-Pacific Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 67.** Asia-Pacific Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 68.** Asia-Pacific Historic Review for Prophylactic Human Vaccines by Product

Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 69.** Asia-Pacific 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## 5A. CHINA

### A. Market Analysis

Outlook

Large Population Offers High Potential

Growth Drivers

China – A Lucrative yet Difficult to Permeate Market

Product Launch

Strategic Corporate Development

Key Players

### B. Market Analytics

**Table 70.** Chinese Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 71.** Chinese Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 72.** Chinese 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## 5B. INDIA

- A. Market Analysis
  - Current & Future Analysis
  - Market Overview
  - Hepatitis B Vaccine in India
  - Combination Vaccines
  - Indian Vaccine Market – Select Combination Vaccines Available in the Country
  - The Patent Act (Third Amendment), 2005
  - Product Launches
  - Strategic Corporate Development
  - Select Players
- B. Market Analytics

**Table 73.** Indian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 74.** Indian Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 75.** Indian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/ Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## **5C. REST OF ASIA-PACIFIC**

- A. Market Analysis
  - Outlook
  - Malaysia – Stricken by Vaccine Shortage
  - Product Launches
  - Strategic Corporate Developments
  - Key Korea-based Player – SK Chemicals Co., Ltd.
- B. Market Analytics

**Table 76.** Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 77.** Rest of Asia-Pacific Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 78.** Rest of Asia-Pacific 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## 6. LATIN AMERICA

### Market Analysis

**Table 79.** Latin American Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 80.** Latin American Historic Review for Prophylactic Human Vaccines by Geographic Region/Country - Brazil, and Rest of Latin America Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 81.** Latin American 14-Year Perspective for Prophylactic Human Vaccines by Geographic Region/Country - Percentage Breakdown of Dollar Sales for Brazil, and Rest of Latin American Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

**Table 82.** Latin American Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 83.** Latin American Historic Review for Prophylactic Human Vaccines by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 84.** Latin American 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## **6A. BRAZIL**

### Market Analysis

**Table 85.** Brazilian Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 86.** Brazilian Historic Review for Prophylactic Human Vaccines by Product Group/ Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 87.** Brazilian 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## **6B. REST OF LATIN AMERICA**

### A. Market Analysis

#### Outlook

#### Product Launches

### B. Market Analytics

**Table 88.** Rest of Latin American Recent Past, Current & Future Analysis for

Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 89.** Rest of Latin American Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)

**Table 90.** Rest of Latin American 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

## 7. REST OF WORLD

### A. Market Analysis

#### Outlook

#### Nigeria: A Severely Underserved Market

**Table 91.** Deaths in Nigerian Children Under Five Years by Cause (2015): Percentage Breakdown of Number of Deaths due to Diarrhoea, Malaria, Measles, Neonatal, Pneumonia, and Others (includes corresponding Graph/Chart)

#### BiondVax Pharmaceuticals Ltd. – A Key Israel-based Player

### B. Market Analytics

**Table 92.** Rest of World Recent Past, Current & Future Analysis for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2015 through 2022 (includes corresponding Graph/Chart)

**Table 93.** Rest of World Historic Review for Prophylactic Human Vaccines by Product Group/Segment - Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets Independently Analyzed with Annual Sales Figures in US\$ Million for Years 2009 through 2014 (includes corresponding Graph/Chart)



**Table 94.** Rest of World 14-Year Perspective for Prophylactic Human Vaccines by Product Group/Segment - Percentage Breakdown of Dollar Sales for Pediatric Prophylactic Vaccines and Adult Prophylactic Vaccines Markets for Years 2009, 2016 & 2022 (includes corresponding Graph/Chart)

#### **IV. COMPETITIVE LANDSCAPE**

Total Companies Profiled: 63 (including Divisions/Subsidiaries - 72)

The United States (22)

Canada (1)

Japan (5)

Europe (14)

    France (3)

    Germany (2)

    The United Kingdom (2)

    Spain (1)

    Rest of Europe (6)

Asia-Pacific (Excluding Japan) (28)

Latin America (1)

Middle East (1)

## I would like to order

Product name: Prophylactic Human Vaccines: Market Research Report

Product link: <https://marketpublishers.com/r/PD857ACD826EN.html>

Price: US\$ 4,950.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PD857ACD826EN.html>